• 908 Devices completed acquisition of Switzerland-based NIRLAB, adding an AI-powered, cloud-connected near-infrared spectroscopy platform for handheld narcotics analysis.
• Purchase consideration included USD 15 million upfront, consisting of USD 13 million cash, USD 2 million in 908 Devices common stock.
• Deal terms include up to an additional USD 8 million in 908 Devices common stock tied to performance milestones over next 20 months.
• NIRLAB device is designed for high-volume field screening, identifying more than 400 drugs in seconds, measuring purity in mixtures, and analyzing cannabis potency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 908 Devices Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605060700BIZWIRE_USPR_____20260506_BW617449) on May 06, 2026, and is solely responsible for the information contained therein.